Human endoplasmic reticulum oxidoreductin 1-α is a novel predictor for poor prognosis of breast cancer

Cancer Science

Volumn 104, Issue 8, 2013, Pages 1091-1096

  Kutomi, Goro ^a   Tamura, Yasuaki ^a   Tanaka, Tsutomu ^a   Kajiwara, Toshimitsu ^a   Kukita, Kazuharu ^a   Ohmura, Tousei ^a   Shima, Hiroaki ^a   Takamaru, Tomoko ^a   Satomi, Fukino ^a   Suzuki, Yasuyo ^a   Torigoe, Toshihiko ^a   Sato, Noriyuki ^a   Hirata, Koichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; COMPLEMENTARY DNA; DNA POLYMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HUMAN ENDOPLASMIC RETICULUM OXIDOREDUCTIN 1 ALPHA; OXIDOREDUCTASE; OXYGEN; PROGESTERONE RECEPTOR; PROTEIN DISULFIDE ISOMERASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE SILENCING; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INVASIVE CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION; TUMOR GROWTH; UNIVARIATE ANALYSIS; VASCULARIZATION; WILD TYPE;

EID: 84881117521     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12177     Document Type: Article

References (17)

1. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009; 26: 19-34.
2. Chaudary N, Hill RP. Hypoxia and metastasis in breast cancer. Breast Dis 2006; 26: 55-64.
3. Milosevic M, Chung P, Parker C et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007; 67: 6022-5.
4. Milosevic M, Warde P, Menard C et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012; 18: 2108-14.
5. Benham AM, Cabibbo A, Fassio A, Bulleid N, Sitia R, Braakman I. The CXXCXXC motif determines the folding, structure and stability of human ERO1-Lalpha. EMBO J 2000; 19: 4493-502.
6. Gess B, Hofbauer KH, Wenger RH, Lohaus C, Meyer HE, Kurtz A. The cellular oxygen tension regulates expression of the endoplasmic oxidoreductase ERO1-Lalpha. Eur J Biochem 2003; 270: 2228-35.
7. Araki K, Nagata K. Functional in vitro analysis of the ERO1 protein and protein-disulfide isomerase pathway. J Biol Chem 2011; 286: 32705-12.
8. Masui S, Vavassori S, Fagioli C, Sitia R, Inaba K. Molecular bases of cyclic and specific disulfide interchange between human ERO1alpha and PDI. J Biol Chem 2011; 286: 16261-71.
9. Tavender TJ, Bulleid NJ. Molecular mechanisms regulating oxidative activity of the ERO1 family in the endoplasmic reticulum. Antioxid Redox Signal 2010; 13: 1177-87.
10. Tanaka S, Uehara T, Nomura Y. Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. J Biol Chem 2000; 275: 10388-93.
11. May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E. ERO1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. Oncogene 2005; 24: 1011-20.
12. Qin C, Wilson C, Blancher C, Taylor M, Safe S, Harris AL. Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis. Clin Cancer Res 2001; 7: 818-23.
13. Schindl M, Schoppmann SF, Samonigg H et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002; 8: 1831-7.
14. Potgens AJ, Lubsen NH, van Altena MC et al. Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem 1994; 269: 32879-85.
15. Claffey KP, Senger DR, Spiegelman BM. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim Biophys Acta 1995; 1246: 1-9.
16. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A 1997; 94: 7192-7.
17. Frand AR, Kaiser CA. ERO1p oxidizes protein disulfide isomerase in a pathway for disulfide bond formation in the endoplasmic reticulum. Mol Cell 1999; 4: 469-77.